2019³â ´ëÇÑÀ̽ÄÇÐȸ Á¦15Â÷ Ãá°èÇмú´ëȸ : 2019-03-16±³À°ÀÏÀÚ : 2019-03-16
±³À°Àå¼Ò : ´ëÀüÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 201È£ ¿Ü 6°³·ë
±³À°ÁÖÁ¦ :
2019³â ´ëÇÑÀ̽ÄÇÐȸ Á¦15Â÷ Ãá°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑÀ̽ÄÇÐȸ
´ã´çÀÚ : ½É¹Î°æ
¿¬¶ôó : 02-484-8052
À̸ÞÀÏ :
mykst@mykst.org ±³À°Á¾·ù : ³»°ú, ¿Ü°ú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
´ëÀü±¤¿ª½Ã±³À°½Ã°£ : 13 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 110,000¿ø
ºñ°í »çÀüµî·Ï Á¤È¸¿ø: 10¸¸¿ø, ÁØȸ¿ø: 5¸¸¿ø, ºñȸ¿ø: 10¸¸¿ø ÇöÀåµî·Ï Á¤È¸¿ø: 11¸¸¿ø, ÁØȸ¿ø: 6¸¸¿ø, ºñȸ¿ø: 11¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 03¿ù 16ÀÏ 07:30~08:00 Registration ()
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 08:00~08:20 Áã ½ÅÀåÀÇ ÇãÇ÷ Àç°ü·ù ¼Õ»ó¿¡¼ »êÈÁú¼Ò(nitric oxide, NO)ÀÇ ¿¹¹æ È¿°ú¿¡ °üÇÑ ¿¬±¸ ¾ÈÇüÁØ(°æÈñÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 08:20~08:40 ½ÉÀåÀÌ½Ä È¯ÀÚ¿¡¼ CMV ƯÀÌ T¼¼Æ÷ ¹ÝÀÀºÐ¼®À» ÅëÇÑ ¸é¿ª¾ïÁ¦ Á¤µµ ÃøÁ¤¹æ¹ý È®¸³ À±Á¾Âù(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 08:40~09:00 ´ç´¢ Áã ½ÅÀåÀÇ ÇãÇ÷-Àç°ü·ù ¼Õ»ó ½Ã DexmedetomidineÀÌ ½Å±â´É º¸È£¿¡ ¹ÌÄ¡´Â È¿°ú ¿¬±¸ ÃÖ¿ë¼±(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 09:00~09:20 Medical issue Ȳ½Å(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 09:20~09:40 Practical issue ±èº¹³à(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 09:40~10:00 Legal issue Á¶¼º¿ë(ÇÑÀϹý·ü¹®Á¦¿¬±¸¼Ò)
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 10:00~10:30 Panel discussion Ȳ½Å(¿ï»êÀÇ´ë), ±èº¹³à(»ï¼º¼¿ïº´¿ø), Á¶¼º¿ë(ÇÑÀϹý·ü¿¬±¸¼Ò), ¼¸í¿ë(Áúº´°ü¸®º»ºÎ)()
ÈÞ½Ä 03¿ù 16ÀÏ 10:30~10:50 Coffee Break ()
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 10:50~11:20 Living liver donors in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study Z. Butt(Northwestern Univ)
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 11:20~11:50 ÀÇ·áÀÌ¿ëµ¥ÀÌÅ͸¦ ÀÌ¿ëÇÑ À̽ĺо߿¡¼ÀÇ ¿¬±¸ÀÇ ¹æÇâ°ú Á¦ÇÑÁ¡ ±èÇöÁ¤(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 11:50~12:20 Modulation of?h?ost immunity by Treg-inducing probiotics ÀÓ½ÅÇõ(Æ÷Ç×°ø´ë)
±âŸ 03¿ù 16ÀÏ 201È£ 12:20~12:40 Àӽà ÃÑȸ ()
½Ä»ç 03¿ù 16ÀÏ 12:40~13:40 Luncheon Symposium ()
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 13:40~14:10 HLA epitope analysis and pathogenesis of de novo DSA ½ÅÈ£½Ä(°í½ÅÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 14:10~14:40 Prediction of De novo DSA: Eplet risk stratification ÀÌÁ¾¼ö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 14:40~15:10 Treat or not to treat de novo DSA positive patients ¾çÀç¼®(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 101È£+102È£ 13:40~14:00 Primary liver cancer Á¤µ¿È¯(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 101È£+102È£ 14:00~14:20 Viral disease (HBV, HCV, and HEV) ¹ÚÁØ¿ë(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 101È£+102È£ 14:20~14:40 Autoimmune liver disease Á¤¼÷Çâ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 101È£+102È£ 14:40~15:00 LT using grafts with metabolic disorders À̳²ÁØ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 101È£+102È£ 15:00~15:10 Q & A ()
±³À°½Ã°£ 03¿ù 16ÀÏ 103È£+104È£ 13:40~14:00 Cardiac amyloidosis ÃÖÈ¿ÀÎ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 103È£+104È£ 14:00~14:20 Candidate with significant pulmonary hypertension ÃÖÁø¿À(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 103È£+104È£ 14:20~14:40 Connective tissue diseases that involoving lung °û½Â±â(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 103È£+104È£ 14:40~15:00 Hematologic malignancies that develop bronchiolitis obliterance after bone marrow transplantation ±è¼öÁ¤(¿¬¼¼ÀÇ´ë)
Åä·Ð 03¿ù 16ÀÏ 103È£+104È£ 15:00~15:10 Panel discussion ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë), Àü°æ¸¸(¼º±Õ°üÀÇ´ë)()
ÈÞ½Ä 03¿ù 16ÀÏ 15:10~15:30 Coffee Break ()
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 15:30~16:00 Banff ºÐ·ùÀÇ ¿ª»ç ¹× °³¿ä ±Ç±â¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 16:00~16:30 Updates on ABMR including C4d-negative ABMR ¹®°æö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 201È£ 16:30~17:00 Chronic TCMR ÇѸ¸ÈÆ(°æºÏÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 101È£+102È£ 15:30~15:45 Surgeon ÃÖ±Ô¼º(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 101È£+102È£ 15:45~16:15 what, how, why, cooperation with a physician ÀÓ¼±¿µ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 101È£+102È£ 16:15~16:45 Laboratory features of transplant suitability ÀÌÇý¿µ(°¡Å縯°üµ¿ÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 101È£+102È£ 16:45~17:00 Case review and discussion È«±Ù(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 103È£+104È£ 15:30~16:05 Donor evaluation and postopeative management in kidney transplantation ÇÑ¿õ±Ô(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 103È£+104È£ 16:05~16:40 Donor evaluation and postopeative management in liver transplantation ÃÖ±Ô¼º(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ 103È£+104È£ 16:40~17:00 Q&A about living donor - º¸Çè, ºñ¿ë, À¯±ÞÈÞ°¡½Åû, ±âÁõ ÈÄ °Ç°°ü¸® ±èÀοÁ(¼¿ï¾Æ»êº´¿ø)